Published in

Oxford University Press (OUP), European Heart Journal, 15(29), p. 1843-1850

DOI: 10.1093/eurheartj/ehn325

Links

Tools

Export citation

Search in Google Scholar

Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention

Journal article published in 2008 by G. Niccoli, S. Giubilato, E. Russ, E. Russo, C. Spaziani, A. Leo, I. Porto, A. M. Leone ORCID, F. Burzotta, Silvia Riondino ORCID, Fabio Maria Pulcinelli, L. M. Biasucci, F. Crea
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Aims Thromboxane A2 (TXA2) is a key mediator of platelet activation and aggregation, and an important mediator of platelet-induced coronary artery constriction. We sought to investigate whether baseline plasma levels of TXA2 are associated with coronary no-reflow after primary percutaneous coronary intervention (PPCI). Methods and results A total of 47 consecutive patients (age, 62.5 +/- 12.7; male sex, 76.6%) admitted to our hospital for a first ST-segment elevation myocardial infarction and undergoing PPCI within 12 h of onset of symptoms were enrolled. Admission TXA2 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA). Angiographic no-reflow was defined as a final TIMI flow of